ERBB2 and breast carcinoma: IPATHER is an ongoing phase Ib trial evaluating the combination of PIK3CAi ipatasertib in combination with pertuzumab + trastuzumab in advanced HER2-positive PI3KCA mutant breast cancer (NCT04253561) [106].